Eli Lilly skyrockets following positive Alzheimer's data

Positive results from phase II trial with drug against Alzheimer's disease, an area also occupying Novo Nordisk, cause Eli Lilly's share price to soar.
Photo: Mike Blake/Reuters/Ritzau Scanpix
Photo: Mike Blake/Reuters/Ritzau Scanpix
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

US pharmaceutical firm Eli Lilly has a 14.2-percent higher indication in the premarket after the company's drug donanemab reached its primary endpoint in a phase II trial with patients against early symptomatic Alzheimer's disease, according to Bloomberg News.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading